LENZ Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $103.54M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | During market hours | $5.50M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | During market hours | $1.90M | $-1.32 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 7, 2026 | During market hours | $1.60M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | $12.50M | $-0.59 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 30, 2025 | Before market open | $5.00M | $-0.53 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | During market hours | – | $-0.53 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 19, 2025 | During market hours | – | $-0.46 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | Before market open | – | $-0.38 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | During market hours | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 20, 2023 | During market hours | – | – | – |
Press releases
Announcements LENZ Therapeutics filed with the SEC
LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
Results of operations · EX-99.1 to Form 8-K
LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
LENZ Therapeutics Announces Commercial Product Availability of VIZZ TM in the United States
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
LENZ Therapeutics Announces US FDA Approval of VIZZ TM for the Treatment of Presbyopia
Other events · EX-99.1 to Form 8-K
LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
LENZ Therapeutics Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
Other events · EX-99.1 to Form 8-K
LENZ Therapeutics Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
Report of Independent Registered Public Accounting Firm
Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress
Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.3 to Form 8-K
Graphite Bio Declares Special Dividend
Regulation FD disclosure · EX-99.1 to Form 8-K
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
timing and completion of the proposed merger by and between Graphite Bio, Inc. (“Graphite”) and LENZ Therapeutics, Inc. (“LENZ”) (the “Merger”); the combined company’s listing on Nasdaq after the closing of
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Graphite Bio Announces Departure of Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results
Results of operations · EX-99 to Form 8-K
Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring
Exit or restructuring costs · Executive or director change · Other events · EX-99 to Form 8-K
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease
Other events · EX-99.1 to Form 8-K
Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64 th ASH Annual Meeting
Other events · EX-99.1 to Form 8-K
Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Graphite Bio Announces Abstracts Accepted for Upcoming 64 th ASH Annual Meeting and Exposition
Other events · EX-99.1 to Form 8-K
Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease
Other events · EX-99.1 to Form 8-K
Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT
Other events · EX-99.1 to Form 8-K/A
Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting
Results of operations · EX-99.1 to Form 8-K
Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease
Regulation FD disclosure · Other events · EX-99 to Form 8-K
Graphite Bio Reports Recent Business Progress and Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K